Cognite Launches "Cognite Embedded" to Accelerate Innovation for Equipment Manufacturers and Industrial Software Builders
10.10.2024 16:17:00 CEST | Business Wire | Press release
Offering empowers OEM's and ISV’s to develop products up to 3X faster and reduce costs of ownership by 80%
Cognite,the Data and AI authority for industry, today announced the launch of Cognite Embedded. This new offering enables Original Equipment Manufacturers (OEMs) and Industrial Software Vendors (ISVs) to accelerate time to market, drastically reduce total cost of ownership, and future-proof their digital solutions with AI-ready architectures, all through Cognite’s leading industrial data platform, Cognite Data Fusion, and low-code industrial agent workbench, Cognite Atlas AI ®.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241009752580/en/

Cognite Launches "Cognite Embedded" to Accelerate Innovation for Equipment Manufacturers and Industrial Software Builders (Photo: Business Wire)
Integrating and contextualizing data is often the biggest hurdle for OEMs and ISVs. Additionally, they need to onboard new customers and roll out data-driven solutions without the high costs associated with maintaining complex custom infrastructures.
Cognite Embedded empowers OEMs and ISVs to accelerate product development by 2-3x and reduce their total cost of ownership by up to 80% by leveraging Cognite Data Fusion’s powerful industrial data modeling features, unique contextualization capabilities that address both structured and unstructured industrial data, and built-in scalability.
Cognite Atlas AI makes it easier to integrate Industrial AI agents into products and solutions for industrial use cases like predictive maintenance and real-time operational optimization, allowing OEMs and ISVs to future-proof their architectures and end-user interfaces.
"By building on Cognite Data Fusion, we've been able to bring our solutions to market at lightning speed," said Arvind Rao, VP Industry Solutions, Data & Analytics, Rockwell Automation. “Partnering with Cognite to develop our FactoryTalk DataMosaix platform has streamlined our development process, allowing us to focus on delivering value to our customers while cutting our time to market significantly. We’re now delivering advanced digital solutions like Energy Management, leveraging Cognite Data Fusion, faster than ever before."
"Cognite's platform has enabled us to seamlessly integrate our offering for reliability- Newton into our customers' systems," said Mark Felder, CTO of Pinnacle Reliability. "Cognite Data Fusion has empowered our services teams to quickly deploy new tools, reports, and data analytics, allowing them to focus on delivery and integration independently from our development teams, which enables us to concentrate on new innovations and bring value to our customers more quickly."
"Partnering with Cognite has empowered us to unlock and utilize data from production operations, fundamentally transforming how we fuel AI and deliver value to our customers through our Lumi platform," said Shashi Menon, VP of Digital Development at SLB. "The scalability and adaptability of Cognite Data Fusion equips us to help our customers harness their production data, optimizing operations through our OptiSite and OptiFlow solutions.”
“The launch of Cognite Embeddedis a testament to Cognite’s commitment to enabling OEMs and ISVs to build and scale the next generation of industrial solutions,” said Girish Rishi, CEO, Cognite. "With Cognite Embedded, equipment and software builders and developers can focus on delivering cutting-edge products without the typical data complexities that slow down innovation. Our platform offers speed, scalability, and the flexibility to integrate AI in a way that future-proofs their solutions for years to come."
The Cognite Embedded offering includes the Embedded Team, a dedicated partner service that will help OEMs and ISVs leverage industrial data for greater efficiency, smarter decision-making, and sustained innovation.
About Cognite
Cognite makes Generative AI work for industry. Leading energy, manufacturing, and power & renewables enterprises choose Cognite to deliver secure, trustworthy, and real-time data to transform their asset-heavy operations to be safer, more sustainable, and more profitable. Cognite provides a user-friendly, secure, and scalable platform that makes it easy for all decision-makers, from the field to remote operations centers, to access and understand complex industrial data, collaborate in real-time, and build a better tomorrow. Visit us at www.cognite.ai and follow us on LinkedIn and X.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241009752580/en/

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 14:23:00 CEST | Press release
–Late-Breaking Prespecified Subgroup Analysis of HELIOS-B Demonstrates that Vutrisiran Provided Consistent Clinical Benefit Across All-Cause Mortality and Recurrent Cardiovascular Events in Patients With or Without Tafamidis Use at Baseline ––Additional Post Hoc Analyses Highlight Positive Impact of Vutrisiran in Addressing the Multisystemic Manifestations of ATTR-CM ––Pooled Analysis Across Four Positive Phase 3 Studies of Vutrisiran and Patisiran Shows Consistent Treatment Effect Across Sexes ––New Subgroup Analysis from KARDIA-3 Phase 2 Study of Zilebesiran Highlights Potential to Provide Enhanced Blood Pressure Control – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR)
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202629.8.2026 23:54:00 CEST | Press release
Qarmousha Pure Ultra White falcon sells for AED 1.5 million at the Abu Dhabi International Hunting and Equestrian Exhibition 2026 (ADIHEX) falcon auction Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom